Skip to Content

Insights From Our Labs to Yours

Covance Blog

  • Home
  • Industry
    • Device
    • Drug
    • Chemical
    • Crop
  • Phase
    • Discovery
    • Preclinical/Nonclinical
    • Phase I-IIa
    • Phase IIb-III
    • Pilot
    • Pivotal
    • Formulation, Packaging, etc.
  • Molecule Type
    • Biologics
    • Small Molecules
    • Biosimilars
    • Biomarkers
    • Cell/Gene Therapies
  • Data/Informatics
    • SEND
    • Modeling
    • Patient Recruitment
    • Xcellerate
  • About Us
    • Careers and Culture
    • Contact Us
    • Covance.com

Jerome Premmereur, VP Patient Safety Solutions & Adjudication, Covance

Home / Jerome Premmereur, VP Patient Safety Solutions & Adjudication, Covance
Covid Vaccine
Share

COVID-19: vaccine innovation and safety at pandemic speed

by Jerome Premmereur, VP Patient Safety Solutions & Adjudication, Covanceupdated on Thursday, July 2, 2020Tuesday, June 30, 2020

Introduction Recently, I was privileged to act as the moderator for a World Drug Safety Congress webinar exploring current considerations for developing and testing COVID-19 vaccine solutions at pandemic speed. Our panel of experts included:

Copyright © 2020 Covance Inc. All rights reserved.